Recent changes at Genentech have brought a wider debate into sharp focus. As the company makes AI increasingly central to its research strategy, several internationally renowned scientists have been let go as part of a broader restructuring and shift in priorities. In a new Comment in Nature Cell Biology, PROXIDRUGS Speaker Ivan Đikić from Goethe University Frankfurt and Henning Walczak from UCL Cancer Institute and University of Cologne ask what such changes could mean for the future of...

A recent report by 17:30 Live Rheinland-Pfalz/Hessen featured a new approach from cancer research in Frankfurt: Prof. Volker Dötsch, PROXIDRUGS researcher, and Dr. Andreas Joerger are working to stabilize mutated variants of the tumor suppressor protein p53. p53 is often referred to as the “guardian of the genome” because it can detect damaged cells and activate important protective mechanisms. In many tumors, however, p53 is mutated and loses its function. One central problem is that many of...

Dr. Johannes Dreizler was awarded the 2026 Kurt Ruths Prize by TU Darmstadt. Endowed with €12,000, the prize recognizes outstanding scientific achievements by early-career researchers. Johannes Dreizler earned his PhD at the Department of Chemistry at TU Darmstadt in the research group of PROXIDRUGS project leader Prof. Felix Hausch. In his dissertation, he developed novel molecular glues for targeted cancer therapy. These compounds bring disease-relevant target proteins into close proximity...